Ozlem Goker-Alpan

Ozlem Goker-Alpan
Born1966 (age 59–60)
TitleFounder and Chief Medical Officer, Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)[1]
Education and training
1984–1990Marmara University School of Medicine (M.D.), Istanbul, Turkey[2]
1992–1996SUNY at Stony Brook, Pediatrics, Stony Brook, New York[2]
1996–1999Greater Washington Medical Genetics Fellowship Program (NIH), Bethesda, Maryland[2]

Ozlem Goker-Alpan is a Turkish-American physician-scientist whose work focuses on lysosomal storage disorders and rare genetic diseases.[2] She is the founder and chief medical officer of the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), a nonprofit organization based in Fairfax, Virginia.[1][3]

Early life

Goker-Alpan was born and raised in Istanbul, Turkey.[2]

Education and training

Goker-Alpan received her medical degree from Marmara University in Istanbul, Turkey.[2] She later completed pediatrics training in the United States and pursued fellowship training in clinical and biochemical genetics at the National Institutes of Health (NIH) through the Greater Washington Medical Genetics program.[2]

Career

Goker-Alpan has worked in clinical and translational research related to lysosomal disorders, including Gaucher's disease and neurologic manifestations associated with variants in the GBA gene.[4] She is associated with the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), which integrates clinical care and research programs in rare diseases.[1][3]

Selected publications

  • Goker-Alpan O, et al. “Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.” Acta Neuropathologica (2010).[4]
  • Weinreb NJ; Goker-Alpan O. “Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent.” JAMA Network Open (2023).[5]

References

  1. ^ a b c "GRIDS Symposium Celebrates its 10th Anniversary". CheckRare. 2025-01-07. Retrieved 2026-02-17.
  2. ^ a b c d e f g "Ozlem Goker-Alpan". SSIEM 2023. Retrieved 2026-02-17.
  3. ^ a b "Lysosomal And Rare Disorders Research And Treatment Center Inc". ProPublica Nonprofit Explorer. Retrieved 2026-02-17.
  4. ^ a b "Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders". PubMed. Retrieved 2026-02-17.
  5. ^ "Ambroxol as Therapy for Gaucher Disease—Ambitious but Ambivalent". PubMed. Retrieved 2026-02-17.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.